Portolan Capital Management, LLC Castle Biosciences Inc Transaction History
Portolan Capital Management, LLC
- $1.26 Billion
- Q3 2024
A detailed history of Portolan Capital Management, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Portolan Capital Management, LLC holds 1,255,628 shares of CSTL stock, worth $34.5 Million. This represents 2.85% of its overall portfolio holdings.
Number of Shares
1,255,628
Previous 1,210,952
3.69%
Holding current value
$34.5 Million
Previous $26.4 Million
35.84%
% of portfolio
2.85%
Previous 2.33%
Shares
19 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$83.7 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$50.2 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$48.1 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$34.7 Million0.61% of portfolio
-
Dimensional Fund Advisors LP Austin, TX865KShares$23.8 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $723M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...